Clinical Trial Update: Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating immune profiling of first-line pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | EARLY_Phase 1 | Status: RECRUITING